- Home
- VERU vs VTGN Comparison
VERU vs VTGN Comparison
Compare VERU & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERU
- VTGN
- Stock Information
- Founded
- VERU 1971
- VTGN 1998
- Country
- VERU United States
- VTGN United States
- Employees
- VERU N/A
- VTGN N/A
- Industry
- VERU Biotechnology: Pharmaceutical Preparations
- VTGN Biotechnology: Pharmaceutical Preparations
- Sector
- VERU Health Care
- VTGN Health Care
- Exchange
- VERU Nasdaq
- VTGN Nasdaq
- Market Cap
- VERU 85.5M
- VTGN 87.2M
- IPO Year
- VERU 1990
- VTGN N/A
- Fundamental
- Price
- VERU $3.60
- VTGN $3.19
- Analyst Decision
- VERU Strong Buy
- VTGN
- Analyst Count
- VERU 3
- VTGN 0
- Target Price
- VERU $33.33
- VTGN N/A
- AVG Volume (30 Days)
- VERU 227.6K
- VTGN 706.2K
- Earning Date
- VERU 08-12-2025
- VTGN 08-07-2025
- Dividend Yield
- VERU N/A
- VTGN N/A
- EPS Growth
- VERU N/A
- VTGN N/A
- EPS
- VERU N/A
- VTGN N/A
- Revenue
- VERU $16,886,419.00
- VTGN $646,000.00
- Revenue This Year
- VERU N/A
- VTGN $23.83
- Revenue Next Year
- VERU N/A
- VTGN $660.39
- P/E Ratio
- VERU N/A
- VTGN N/A
- Revenue Growth
- VERU 337.24
- VTGN N/A
- 52 Week Low
- VERU $2.64
- VTGN $1.90
- 52 Week High
- VERU $14.20
- VTGN $3.79
- Technical
- Relative Strength Index (RSI)
- VERU 35.24
- VTGN 56.96
- Support Level
- VERU $2.64
- VTGN $2.96
- Resistance Level
- VERU $3.69
- VTGN $3.58
- Average True Range (ATR)
- VERU 0.39
- VTGN 0.22
- MACD
- VERU 0.02
- VTGN -0.01
- Stochastic Oscillator
- VERU 40.27
- VTGN 43.68
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.